A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Trial Profile

A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs RGX 314 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors REGENXBIO
  • Most Recent Events

    • 23 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 06 Jan 2017 According to a REGENXBIO media release, the company plans to begin enrollment in the trial in mid-2017 and present interim update from the study in late 2017.
    • 06 Jan 2017 According to a REGENXBIO media release, the company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) during the first week of 2017 to support this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top